BIOS Capital Management’s IN8bio INAB Stock Holding History

BIOS Capital Management’s Portfolio INAB Stock Details INAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$114K	Sell	80,957 -86,848	-52%	-$131K	0.27%	6
2026 Q1	$248K	Sell	167,805 -85,612	-34%	-$166K	0.47%	6
2025 Q4	$593K	Sell	253,417 -33,247	-12%	-$63.2K	0.72%	6
2025 Q3	$622K	Hold	286,664	–	–	0.7%	6
2025 Q2	$599K	Sell	286,664 -3	-0%	-$12	0.83%	6
2025 Q1	$1.43M	Hold	286,667	–	–	1.8%	5
2024 Q4	$2.21M	Buy	+286,667	New	+$2.52M	2.35%	5

Other funds holding INAB

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Oppenheimer & Co New York $9.37B AUM 36.4% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

CAPTRUST Financial Advisors Raleigh, North Carolina $65.5B AUM 24.25% 1-Year Est. Return

BIOS Capital Management's INAB Position: Q2 2026 in Review

BIOS Capital Management reduced its IN8bio (INAB) stake by 52% in Q2 2026, selling an estimated $131K and leaving 80,957 shares worth $114K. The position accounts for 0.27% of the portfolio, ranked #6.

BIOS Capital Management first reported a position in INAB in Q4 2024 and has held it in 7 quarters since. The position peaked at $2.21M in Q4 2024. 21 funds tracked by Wall St. Rank hold INAB as of Q2 2026.

BIOS Capital Management held 80,957 shares of IN8bio worth $114K as of Q2 2026.
BIOS Capital Management sold 86,848 IN8bio shares in Q2 2026, an estimated $131K.
IN8bio made up 0.27% of BIOS Capital Management's portfolio in Q2 2026, its #6 holding.
BIOS Capital Management first reported a position in IN8bio in Q4 2024 and has held it in 7 quarters since.
BIOS Capital Management's IN8bio position peaked at $2.21M in Q4 2024.
21 funds tracked by Wall St. Rank held IN8bio as of Q2 2026.

Based on BIOS Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.